Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 14.98M P/E - EPS this Y -42.30% Ern Qtrly Grth -
Income -12.47M Forward P/E -0.96 EPS next Y 36.60% 50D Avg Chg 12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -62.00%
Dividend N/A Price/Book 0.73 EPS next 5Y - 52W High Chg -99.00%
Recommedations 1.00 Quick Ratio 3.76 Shares Outstanding 4.91M 52W Low Chg 52.00%
Insider Own 61.67% ROA -35.26% Shares Float 4.71M Beta -0.46
Inst Own 1.37% ROE -64.89% Shares Shorted/Prior 51.85K/68.43K Price 0.55
Gross Margin - Profit Margin - Avg. Volume 380,464 Target Price 36.50
Oper. Margin - Earnings Date May 10 Volume 1,373,472 Change 9.69%
About NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

NeuroBo Pharmaceuticals, Inc. News
04/23/24 NRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…
04/17/24 NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
04/01/24 NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
03/28/24 NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
03/13/24 NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
03/04/24 NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
02/29/24 NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
02/12/24 NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
02/01/24 NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
01/18/24 NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
01/18/24 NRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…
01/09/24 NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
01/02/24 NeuroBo to Participate in Industry and Investor Conferences in January
12/28/23 NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
12/19/23 NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
12/15/23 Life Science Investor Forum: Presentations Now Available for Online Viewing
12/12/23 Life Science Investor Forum Agenda Announced for December 14th, 2023
12/01/23 NeuroBo to Participate in Investor Conferences in December
11/13/23 NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/06/23 NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
NRBO Chatroom

User Image thestockthing Posted - 2 days ago

$NRBO I was curious how much under 3$ it would hang again and today it wasn’t for long.

User Image RollingDollar Posted - 2 days ago

$NRBO

User Image jonnyloitering Posted - 4 days ago

$NRBO Good luck filling that huge order at 2.91. Why in the hell would someone short this at these levels? There is obviously very little sell pressure as indicated by the volume. It's flat and will likely remain so for sometime. Keep shaking, any longs left are not going anywhere. Dong A is obviously not selling their shares, that leaves only a few million shares trading and like me they are not selling.

User Image Stock_Titan Posted - 1 week ago

$NRBO NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity https://www.stocktitan.net/news/NRBO/neuro-bo-pharmaceuticals-doses-first-patient-in-its-phase-1-clinical-a9ya7b2lvqjg.html

User Image jonnyloitering Posted - 2 weeks ago

$NRBO Meh... Par for the course when investing in small biopharms. Something to keep in mind though, is that it is a 4 million share float that Dong A owns 60% of. They will maintain that ratio to keep the controlling interest. Basically, more than half of any dilution will be swallowed up immediately by them. It takes money to bring it to the finish line, and now they have the ability to do so. I will maintain my strategy of averaging down at opportune drops. Cheers.

User Image SelfMafia Posted - 2 weeks ago

$NRBO $150M DILUTION

User Image DonCorleone77 Posted - 2 weeks ago

$NRBO NeuroBo Pharmaceuticals files $150M mixed securities shelf

User Image invbond Posted - 2 weeks ago

$NRBO Down but holding it long term

User Image PopPortfolios Posted - 2 weeks ago

$NRBO did warn you 😬

User Image jonnyloitering Posted - 2 weeks ago

$NRBO

User Image Akubra Posted - 2 weeks ago

$NRBO Are we going to bottom out? This is a free fall

User Image broadview19 Posted - 2 weeks ago

$NRBO Oh @jonnyloitering where are you? Another great day for NRBO!

User Image RollingDollar Posted - 2 weeks ago

$NRBO

User Image AggressiveHulk Posted - 2 weeks ago

$GNLN Over 1m short volume in the last 3 trading days, and that is not counting the naked shorts. MMs are going to send this very soon but want to shake out as many weak hands as possible. Just buy and hold and watch what happens. The penny flippers are stupid and do not understand how a super trend squeeze works. Be smart and watch the gifts come your way. Targeting 4.5+ 🎯 $NRBO $EOSE $SNTG 3 other names that i have on my radar for possible swing ups! Goodluck to all traders wish you the best

User Image jonnyloitering Posted - 3 weeks ago

$NRBO Daily chart sporting a gravestone doji for today. See what tomorrow brings.

User Image jonnyloitering Posted - 3 weeks ago

$NRBO Still here shitstick.

User Image broadview19 Posted - 3 weeks ago

$NRBO Longs are long gone!

User Image Arttab Posted - 3 weeks ago

$NRBO Nice play to average down. Be sure what you have in hand !

User Image Stock_Titan Posted - 3 weeks ago

$NRBO NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH https://www.stocktitan.net/news/NRBO/neuro-bo-pharmaceuticals-completes-enrollment-of-part-1-of-its-phase-r65jtivx7m0q.html

User Image Stock_Titan Posted - 03/28/24

$NRBO NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update https://www.stocktitan.net/news/NRBO/neuro-bo-pharmaceuticals-reports-year-end-2023-financial-results-and-s3cbbkszmy8j.html

User Image jonnyloitering Posted - 1 month ago

$NRBO Scuzzy is the word that comes to mind when you use innuendo with no basis in reality to create FUD. That kind of intellectual dishonesty chaps my ass. Have a nice day.

User Image Htsone Posted - 1 month ago

$NRBO Scuzzy is the word that comes to mind. Gemphire was the worst.

User Image jonnyloitering Posted - 1 month ago

$NRBO I would really like to see the Term sheet with Mthra for nb-01. As of right now it's the only incoming funds we can hope for to prevent dilution. I would imagine we will be owed milestone payments upon engagement of a phase 3 trial. Phase 2 results seemed promising. I do hope they are working to sell off other legacy assets. Hopefully Q4 report will shed some light.

User Image broadview19 Posted - 1 month ago

$NRBO Where's all the delusional bulls? Crickets!

User Image Jw242 Posted - 1 month ago

$NRBO oh well. Glad I’m playing with profits.

User Image broadview19 Posted - 1 month ago

$NRBO Markets rumbling to ATH's and this rumbling to all time lows. It must be Joe's fault.

User Image Jw242 Posted - 1 month ago

$NRBO any thoughts on MDGL approval for MASH, and the potential effect here?

User Image jonnyloitering Posted - 1 month ago

$NRBO Well, my position here is not doing hot, but it will bounce back. My other bio position that I took a couple of months ago in SLS however, is kicking some serious ass.

User Image broadview19 Posted - 1 month ago

$NRBO What are all the excuses today with longs?

User Image Alkozaii Posted - 1 month ago

$NRBO need some good PR